1218 - Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with An Inadequate Response to Methotrexate

Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Kazuhiko Yamamoto, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Tsutomu Takeuchi, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan, Naoki Ishiguro, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, Yoshiya Tanaka, University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, Katsumi Eguchi, Sasebo City General Hospital, Sasebo, Nagasaki, Japan, Akira Watanabe, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, Hideki Origasa, University of Toyama School of Medicine, Toyama, Toyama, Japan, Toshiharu Shoji, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, Yoshiharu Sakamaki, UCB Inc, Chiyoda, Tokyo, Japan, Nobuyuki Miyasaka, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan and Takao Koike, Sapporo Medical Center NTT EC, Sapporo, Japan
Presentation Number: 1218

Background/Purpose: Certolizumab pegol (CZP) as add-on therapy to methotrexate (MTX) provided rapid and sustained efficacy in RA patients (pts) in multiple international clinical trials.1,2 The objective of this study was to investigate the efficacy and safety of CZP + MTX in Japanese pts with active RA and an inadequate response to MTX.

Method: In this 24-week (wk), Phase II/III, multicenter, double-blind, randomized, placebo-controlled, study (NCT00791999), Japanese pts with active RA and an inadequate response to MTX were randomized (1:1:1:1) to 1 of 4 treatment groups: CZP 100, 200, or 400 mg or placebo (PBO) + MTX every 2 wks (Q2W). Per study design, pts in the CZP groups received induction dosing with 200 mg (100 mg group) or 400 mg (200 and 400 mg groups) at Wks 0, 2, and 4. Pts who did not achieve an ACR20 response at Wks 12 and 14 were withdrawn from the study at Wk 16 and were eligible to enter an open-label extension study, as were pts completing the study. Primary efficacy end point was ACR20 response at Wk 12.

Result: A total of 316 pts were randomized. Demographic and baseline (BL) characteristics were similar between treatment groups: RA disease duration ranged from 5.6 to 6.0 years, DAS28(ESR) from 6.19 to 6.46, HAQ-DI from 1.12 to 1.19, and MTX dose from 7.4 to 7.6 mg/wk across groups. The primary end point was met; ACR20 and ACR50 response rates were significantly higher in each CZP group compared with PBO at Wks 12 and 24 (Table). Differences in CZP ACR20 response rates vs PBO were significant as early as Wk 1 and sustained to Wk 24. At Wk 24, mean radiographic progression from BL was reduced, and more pts were mTSS non-progressors in the CZP-treated groups vs PBO; differences seen with the 100 mg Q2W dose were not significant vs PBO. Improvements in all ACR core set of disease activity measures, including physical function, were observed as early as Wk 1 and were sustained to Wk 24 at all CZP doses. CZP was well tolerated and no new safety signals were identified. SAEs ranged from 4.2% to 5.9% in the CZP groups (with 4 pts developing serious infections or infestations) vs 1.3% in the PBO group. There were no cases of TB or deaths.

Conclusion: Treatment with CZP + MTX resulted in a rapid and sustained reduction in RA signs and symptoms, inhibited progression of structural joint damage, and improved physical function in Japanese RA pts with an inadequate response to MTX. The 200 mg Q2W maintenance dose showed numerically greater clinical efficacy and better inhibition of radiographic progression compared with the 100 mg Q2W dose. No additional benefit was observed with the 400 mg Q2W dose vs the 200 mg Q2W dose. These results confirm the findings of the RAPID studies1, 2 and substantiate 200 mg Q2W as the optimal maintenance dosing for CZP.

References

1. Keystone E, et al. Arthritis Rheum 2008;58:33193329.

2. Smolen J, et al. Ann Rheum Dis 2009;68:797804.


Keywords: Anti-TNF therapy, Certolizumab pegol, Japan and rheumatoid arthritis, treatment

Disclosure: K. Yamamoto, Otsuka Pharmaceutical Co., Ltd, 5 ; T. Takeuchi, Ostsuke Pharmaceutical Co., Ltd, 5, UCB Inc, 5 ; H. Yamanaka, Otsuka Pharmaceutical Co., Ltd, 5, Otsuka Pharmaceutical Co., Ltd, 2, UCB Inc, 5, UCB Inc, 2 ; N. Ishiguro, Otsuka Pharmaceutical Co., Ltd, 5 ; Y. Tanaka, Otsuka Pharmaceutical Co., Ltd, 5 ; K. Eguchi, Otsuka Pharmaceutical Co., Ltd, 5 ; A. Watanabe, Otsuka Pharmaceutical Co., Ltd, 5 ; H. Origasa, Ostsuka Pharmaceutical Co., Ltd, 5 ; T. Shoji, Otsuka Pharmaceutical Co., Ltd, 3 ; Y. Sakamaki, UCB Inc, 3 ; N. Miyasaka, Otsuka Pharmaceutical Co., Ltd, 5 ; T. Koike, Otsuka Pharmaceutical Co., Ltd, 5 .